Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes

European Journal of Immunology

Volumn 46, Issue 1, 2016, Pages 230-241

  Tooley, James E ^a   Vudattu, Nalini ^a   Choi, Jinmyung ^a   Cotsapas, Chris ^a   Devine, Lesley ^a   Raddassi, Khadir ^a   Ehlers, Mario R ^c   Mcnamara, James G ^b   Harris, Kristina M ^c   Kanaparthi, Sai ^c   Phippard, Deborah ^c   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Immune Tolerance Network   (United States)

Author keywords

Anti CD3 mAb; CD8+ T cells; Immune therapy; Tolerance; Type 1 diabetes

Indexed keywords

C PEPTIDE; CD4 ANTIGEN; CD8 ANTIGEN; FC RECEPTOR; TEPLIZUMAB; MONOCLONAL ANTIBODY; TRANSCRIPTOME;

ADOLESCENT; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATOR GENE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTE SUBSETS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84953839594     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545708     Document Type: Article

References (34)

1. Herold, K., Vignali, D. A., Cooke, A. and Bluestone, J., Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 2013. 13: 243-256.
2. Coppieters, K. T., Dotta, F., Amirian, N., Campbell, P. D., Kay, T. W., Atkinson, M. A., Roep, B. O. et al., Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 2012. 209: 51-60.
3. Hagopian, W., Ferry, R. J., Jr., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E. et al., Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013. 62: 3901-3908.
4. Herold, K. C., Gitelman, S., Greenbaum, C., Puck, J., Hagopian, W., Gottlieb, P., Sayre, P. et al., Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 2009. 132: 166-173.
5. Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K. D. et al., Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013. 62: 3766-3774.
6. Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K. et al., A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005. 54: 1763-1769.
7. Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J. et al., Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013. 56: 391-400.
8. Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E. et al., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002. 346: 1692-1698.
9. Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F. et al., Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005. 352: 2598-2608.
10. Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Jr., Bode, B. et al., Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011. 378: 487-497.
11. Cernea, S. and Herold, K. C., Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin. Immunol. 2010. 134: 121-129.
12. Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J. et al., Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013. 56: 391-400.
13. Orban, T., Beam, C. A., Xu, P., Moore, K., Jiang, Q., Deng, J., Muller, S. et al.; Type 1 Diabetes TrialNet Abatacept Study Group, Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 2014. 63: 3449-3457.
14. Rigby, M., DiMeglio, L., Rendell, M., Felner, E., Dostou, J., Gitelman, S., Patel, C. et al., Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the TIDAL study. Lancet Diabetes Endocrinol. 2013. 1: 284-294.
15. Ablamunits, V., Bisikirska, B. and Herold, K. C., Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur. J. Immunol. 2010. 40: 2891-2901.
16. + T cells activated with anti-CD3 antibody. Eur. J. Immunol. 2011. 41: 1832-1842.
17. Belghith, M., Bluestone, J. A., Barriot, S., Megret, J., Bach, J. F. and Chatenoud, L., TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 2003. 9: 1202-1208.
18. Bisikirska, B., Colgan, J., Luban, J., Bluestone, J. A. and Herold, K. C., TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs. J. Clin. Invest. 2005. 115: 2904-2913.
19. Waldron-Lynch, F., Henegariu, O., Deng, S., Preston-Hurlburt, P., Tooley, J., Flavell, R. and Herold, K. C., Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 2012. 4: 118ra112.
20. Esplugues, E., Huber, S., Gagliani, N., Hauser, A. E., Town, T., Wan, Y. Y., O'Connor, W., Jr. et al., Control of TH17 cells occurs in the small intestine. Nature 2011. 475: 514-518.
21. Hor, S., Pirzer, H., Dumoutier, L., Bauer, F., Wittmann, S., Sticht, H., Renauld, J. C. et al., The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J. Biol. Chem. 2004. 279: 33343-33351.
22. Nikoopour, E., Bellemore, S. M. and Singh, B., IL-22, cell regeneration and autoimmunity. Cytokine 2015. 74: 35-42.
23. Swafford, A. D., Howson, J. M., Davison, L. J., Wallace, C., Smyth, D. J., Schuilenburg, H., Maisuria-Armer, M. et al., An allele of IKZF1 (Ikaros) conferring susceptibility to childhood acute lymphoblastic leukemia protects against type 1 diabetes. Diabetes 2011. 60: 1041-1044.
24. You, S., Zuber, J., Kuhn, C., Baas, M., Valette, F., Sauvaget, V., Sarnacki, S. et al., Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. Am. J. Transplant 2012. 12: 2909-2919.
25. Chatenoud, L., Primo, J. and Bach, J. F., CD3 antibody-induced dominant self-tolerance in overtly diabetic NOD mice. J. Immunol. 1997. 158: 2947-2954.
26. + graft infiltrating cells. Am. J. Transplant. 2013. 13: 1655-1664.
27. Arif, S., Moore, F., Marks, K., Bouckenooghe, T., Dayan, C. M., Planas, R., Vives-Pi, M. et al., Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011. 60: 2112-2119.
28. Arif, S., Tree, T. I., Astill, T. P., Tremble, J. M., Bishop, A. J., Dayan, C. M., Roep, B. O. et al., Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 2004. 113: 451-463.
29. Gao, W., Thompson, L., Zhou, Q., Putheti, P., Fahmy, T. M., Strom, T. B. and Metcalfe, S. M., Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle 2009. 8: 1444-1450.
30. Keymeulen, B., Candon, S., Fafi-Kremer, S., Ziegler, A., Leruez-Ville, M., Mathieu, C., Vandemeulebroucke, E. et al., Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010. 115: 1145-1155.
31. Reimann, K. A., Chernoff, M., Wilkening, C. L., Nickerson, C. E. and Landay, A. L., Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin. Diagn. Lab. Immunol. 2000. 7: 352-359.
32. Bolstad, B. M., Collin, F., Simpson, K. M., Irizarry, R. A. and Speed, T. P., Experimental design and low-level analysis of microarray data. Int. Rev. Neurobiol. 2004. 60: 25-58.
33. Bolstad, B. M., Irizarry, R. A., Astrand, M. and Speed, T. P., A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003. 19: 185-193.
34. Le, S., Josse, J. and Husson, F., Factomine R. J. Statist. Softw. 2008. 25.